Navigation Links
US Oncology Continues to Set the Standard as a VAWD(CM) Accredited Wholesale Distributor
Date:5/14/2010

THE WOODLANDS, Texas, May 14 /PRNewswire/ -- US Oncology, Inc.'s Fort Worth, Texas distribution facility, US Oncology Specialty, LP, has once again successfully passed the National Association of Boards of Pharmacy® (NABP®) Verified-Accredited Wholesale Distributors(CM) (VAWD(CM)) program's comprehensive criteria review and on-site inspection.

US Oncology Specialty, a specialty distribution center service of US Oncology, was originally accredited in 2006, earning the distinction of being the first oncology-specific wholesale distributor accredited by NABP.  The VAWD program supports state board of pharmacy efforts to regulate the drug supply chain, and represents a concerted and cooperative effort between NABP and accredited wholesale distributors to protect the public from counterfeit drugs and continue to secure the integrity of the US medication distribution supply chain.

VAWD accreditation assures that wholesale distributors like US Oncology Specialty are appropriately licensed, have undergone intense background checks, and employ security and due diligence practices for safely distributing prescription drugs.

"US Oncology is proud to say our accreditation has been renewed," said Rolando DeCardenas, vice president & general manager of US Oncology Specialty.  "This assures the public and, especially, patients that we are a premier and highly qualified wholesale distributor who takes pride in our work. It's all about advancing cancer care.  This is our way of meeting that ultimate goal."

The VAWD program is a rigorous one. Accreditation is achieved by:

  • Performing extensive evaluation of wholesale distributors' licensure status;
  • Conducting disciplinary screening through the NABP Clearinghouse;
  • Performing criminal and financial background checks on key employees;
  • Reviewing policies and procedures; and
  • Completing on-site inspections of wholesale distributor facilities with the assurances of NABP that the wholesale distributor is operating legally and in conformance with state laws and regulations.

"The VAWD accreditation program maintains high standards for safeguarding the wholesale drug distribution chain, and US Oncology Specialty, LP continues to prove that they meet these rigorous standards," said NABP President Gary A. Schnabel, RN, RPh. "NABP congratulates US Oncology on their dedication to keeping patients safe. As one of the first wholesale distributors to become accredited, US Oncology was at the forefront of this program, which now has more than 400 accredited wholesale distributors."

In 2005, US Oncology launched US Oncology Specialty to facilitate the seamless flow of oncology pharmaceuticals directly from the pharmaceutical manufacturers to its nationwide network of practices.  In 2007, US Oncology continued to raise the bar by being the first oncology distributor to implement an electronic pedigree (ePedigree) data management solution within its oncology drug distribution system.  ePedigree secures the supply chain of pharmaceuticals distributed to the US Oncology network of affiliated practices.

This innovative technology is just another way US Oncology is ensuring the integrity of every drug distributed through its nationwide network.  Every drug is protected with an ePedigree track and trace system that documents the drug's history in the distribution channel.

"As one of the nation's largest healthcare service networks dedicated exclusively to cancer treatment and research, US Oncology takes great pride in having an accredited wholesale distribution center that helps ensure a safe and secure supply chain from the manufacturer to the patient," said Bruce Broussard, Chairman and CEO of US Oncology.  

"This accreditation shows just how much time and effort we invest in our state-of-the-art distribution system and security measures," said DeCardenas.  "Oncologists in the United Network of US Oncology, as well as their patients, can have confidence in the integrity of the drugs we deliver to them."

About US Oncology

US Oncology, Inc. is the nation's leading integrated oncology company. By uniting the largest community-based cancer treatment and research network in America, US Oncology expands patient access to high-quality care and advances the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology is affiliated with more than 1,300 community-based oncologists, and works with patients, hospitals, payers, and the medical industry across all phases of the cancer research and delivery system. By promoting the use of innovative technology, clinical research, evidence-based medicine and shared best practices, US Oncology improves patient outcomes and offers a better patient experience. For more information, visit www.usoncology.com.

About US Oncology Specialty, LP

US Oncology provides community oncology practices with cancer therapy drugs that are safe and unadulterated. Through its VAWD® certified drug distribution center, US Oncology Specialty, located in Fort Worth, Texas, protects the integrity of drugs administered to patients via state-of-the-art ePedigree technology that tracks drug therapies from manufacturer to patient, ensuring that drugs administered are genuine and unadulterated. For more information, visit www.oncologyrx.us.

About NABP

NABP is an independent, international, and impartial association that assists its member boards and jurisdictions in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Spherix Incorporated (Nasdaq: SPEX ) -- an ... monetization of intellectual property, today provided an update on ... Northern District of Texas and ... Inter Partes Re-examination ("IPR") proceedings that VTech ... IPR was initiated on only certain claims of two ...
(Date:2/4/2016)... Strasbourg, France , to the US ... Strasbourg, France , to the US company Advanced Bioscience ... announce that it acted as an advisor to Transgene on ... Strasbourg, France , to the US company Advanced Bioscience ... Transgene (Euronext: TNG), a member of Institut Mérieux, is ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
(Date:2/3/2016)... YORK and HOLLISTON, Mass., Feb. 3, 2016 ... HART ), a biotechnology company developing bioengineered ... trachea and bronchus, today announced that CEO ... BIO CEO & Investor Conference on Tuesday, ... New York City . HART,s ...
Breaking Biology Technology:
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)... BELL, Pa. , Jan. 25, 2016   Unisys Corporation ... recognition system at John F. Kennedy (JFK) International Airport, ... Border Protection (CBP) identify imposters attempting to enter ... do not belong to them. pilot testing of ... out initially at three terminals at JFK during January 2016. ...
(Date:1/21/2016)... January 21, 2016 ... new market research report "Emotion Detection and Recognition Market by ... Tools (Facial Expression, Voice Recognition and Others), Services, ... forecast to 2020", published by MarketsandMarkets, the global ... reach USD 22.65 Billion by 2020, at a ...
Breaking Biology News(10 mins):